SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Edward W. Richmond who wrote (1146)2/4/2001 12:51:13 PM
From: Ian@SI  Read Replies (1) of 1321
 
Ed,

AT the QLT website, I was looking at the Opthalmology pipeline and saw this statement.

"The U.S. FDA recently assigned priority review status to the supplemental New Drug Application
(sNDA) for Visudyne™ therapy filed August 14, 2000 by Novartis Ophthalmics and QLT for the
treatment of eye diseases beyond AMD. The companies are seeking to expand the initial
indication to include patients with other ocular conditions characterized by CNV including CNV due
to pathologic myopia and ocular histoplasmosis syndrome. "

Details at: qlt-pdt.com

I don't remember the Priority review status. Do you know whether that happened in August or whether it was more recent than that. i.e. - Will the FDA rule within the next month, or migth it take a little longer?

With earnings coming on Thursday, Tamara is probably going to have a hectic week, so any info you can provide will be appreciated.

Thanks,
Ian.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News